Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - palonosetron hydrochloride, quantity: 280 microgram (equivalent: palonosetron, qty 250 microgram) - injection, solution - excipient ingredients: water for injections; sodium acetate trihydrate; mannitol; hydrochloric acid; sodium hydroxide - palonosetron injection is indicated for prevention of nausea and vomiting induced by cytotoxic chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - palonosetron hydrochloride, quantity: 280 microgram (equivalent: palonosetron, qty 250 microgram) - injection, solution - excipient ingredients: mannitol; sodium acetate trihydrate; water for injections; hydrochloric acid; sodium hydroxide - palonosetron injection is indicated for prevention of nausea and vomiting induced by cytotoxic chemotherapy.

Israel - English - Ministry of Health

a.l. medi-market ltd. - palonosetron as hydrochloride - solution for injection - palonosetron as hydrochloride 50 mcg / 1 ml - palonosetron - palonosetron seacross is indicated in adults and in paediatric patients 1 month of age and older for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy, and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - palonosetron hydrochloride, quantity: 0.28 mg - injection, solution - excipient ingredients: citric acid monohydrate; hydrochloric acid; water for injections; sodium citrate dihydrate; sodium hydroxide; mannitol; disodium edetate - palonosetron medicianz is indicated for:,? prevention of nausea and vomiting induced by cytotoxic chemotherapy,? prevention of postoperative nausea and vomiting (ponv) for up to 24 hours following surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - palonosetron hydrochloride, quantity: 0.28 mg - injection, solution - excipient ingredients: sodium citrate dihydrate; citric acid monohydrate; water for injections; mannitol; hydrochloric acid; disodium edetate; sodium hydroxide - palonosetron medsurge is indicated for:,? prevention of nausea and vomiting induced by cytotoxic chemotherapy,? prevention of postoperative nausea and vomiting (ponv) for up to 24 hours following surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

juniper biologics pty ltd - palonosetron hydrochloride, quantity: 56 microgram/ml (equivalent: palonosetron, qty 50 microgram/ml) - injection, solution - excipient ingredients: sodium hydroxide; disodium edetate; hydrochloric acid; sodium citrate dihydrate; mannitol; water for injections; citric acid monohydrate - aloxi is indicated for: - prevention of nausea and vomiting induced by cytotoxic chemotherapy. - prevention of postoperative nausea and vomiting (ponv) for up to 24 hours following surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

juniper biologics pty ltd - palonosetron hydrochloride, quantity: 56 microgram/ml (equivalent: palonosetron, qty 50 microgram/ml) - injection, solution - excipient ingredients: sodium hydroxide; disodium edetate; hydrochloric acid; sodium citrate dihydrate; mannitol; water for injections; citric acid monohydrate - aloxi is indicated for: - prevention of nausea and vomiting induced by cytotoxic chemotherapy. - prevention of postoperative nausea and vomiting (ponv) for up to 24 hours following surgery.

Canada - English - Health Canada

knight therapeutics inc. - palonosetron (palonosetron hydrochloride); netupitant - capsule - 0.5mg; 300mg - palonosetron (palonosetron hydrochloride) 0.5mg; netupitant 300mg - antiemetics

United States - English - NLM (National Library of Medicine)

helsinn therapeutics (u.s.), inc. - palonosetron hydrochloride (unii: 23310d4i19) (palonosetron - unii:5d06587d6r) - aloxi capsules are indicated in adults for the prevention of acute nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. aloxi is contraindicated in patients known to have hypersensitivity to palonosetron [see warnings and precautions (5.1)]. risk summary there are no available data on palonosetron hcl use in pregnant women to inform a drug-associated risk. in animal reproduction studies, no effects on embryo-fetal development were observed with the administration of oral palonosetron hcl during the period of organogenesis at doses up to 921 and 1,841 times the recommended human oral dose in rats and rabbits, respectively (see data) . the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized p

United States - English - NLM (National Library of Medicine)

helsinn therapeutics (u.s.), inc. - palonosetron hydrochloride (unii: 23310d4i19) (palonosetron - unii:5d06587d6r) - aloxi injection is indicated in adults for prevention of: - acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (mec). - acute nausea and vomiting associated with initial and repeat courses highly emetogenic cancer chemotherapy (hec). - postoperative nausea and vomiting (ponv) for up to 24 hours following surgery. efficacy beyond 24 hours has not been demonstrated. as with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. in patients where nausea and vomiting must be avoided during the postoperative period, aloxi is recommended even where the incidence of postoperative nausea and/or vomiting is low. aloxi injection is indicated in pediatric patients 1 month to less than 17 years of age for prevention of: - acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly e